Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients (age ≥18 years)
Diagnosis of severe eosinophilic asthma requiring stable treatment of high doses of inhaled corticosteroids and a long-acting agonist β2 ± additional asthma controller
Received at least one dose of benralizumab during the individualized access program period (March-December of 2018)
Informed consent signed
You may not be if
Patients enrolled in a clinical trial who received benralizumab during the same period of the individualized access program
Refuse to sign the informed consent
Clareo Health | Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
